Clinical Trials Browser

Ototoxicity × Clear all

NCT06036407 2026-04-14

HEAR

Phase NA Completed

Ototoxicity, Neoplasms, Hearing Loss

NCT06553157 2026-01-20

Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy

Phase 1/2 Completed

Ototoxicity

NCT05789316 2026-01-12

Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

Phase NA Completed

Ototoxicity, Head and Neck Neoplasms, Hearing Loss

NCT02425397 2025-12-01

OTOPLAT

Ototoxicity, Neoplasms, Hearing Loss

NCT05936034 2025-11-28

PROTOTOX

Phase NA Recruiting

Ototoxicity, Hearing Disorders, Neoplasms

NCT05756660 2025-10-20

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

Phase EARLY_PHASE1 Suspended

Gastrointestinal

Ototoxicity, Neoplasms, Germ Cell and Embryonal, Hepatoblastoma

NCT06957132 2025-05-04

RISP-OTOTOX

Phase NA Not yet recruiting

Ototoxicity, Neoplasms

NCT06551857 2025-04-16

CaSPiN

Ototoxicity, Neoplasms, Hearing Loss, Cognitive Dysfunction

NCT06929468 2025-04-16

Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer

Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Ototoxicity, Deafness, Dizziness, Head and Neck Neoplasms, Hearing Loss, Sensorineural, Vestibular Diseases, Hearing Loss

NCT05641441 2025-01-13

Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma

Ototoxicity, Neuroma, Acoustic, Hearing Loss

NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Phase 2 Recruiting

Ototoxicity, Mucositis

NCT06490029 2024-07-08

BIO-OTOTOX

Ototoxicity

NCT06297369 2024-03-07

Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients

Phase 2 Unknown

Ototoxicity, Peripheral Nervous System Diseases

NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Phase 3 Completed

131 enrolled 18 charts 1 FDA

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

NCT05946577 2023-07-14

AURACCO

Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Ototoxicity, Head and Neck Neoplasms, Salivary Gland Neoplasms, Tinnitus, Hearing Loss

NCT04262336 2023-07-06

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Phase 1 Completed

Ototoxicity, Hearing Loss

NCT02890030 2020-04-08

The Platinum Study Comparison Group

Ototoxicity, Testicular Neoplasms, Neurotoxicity Syndromes

NCT01848457 2020-03-16

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Phase 2 Completed

13 enrolled 15 charts

Ototoxicity, Neoplasms, Osteosarcoma

NCT00652132 2018-05-29

SIOPEL6

Phase 3 Completed

116 enrolled 1 FDA

Gastrointestinal

Ototoxicity, Liver Neoplasms, Hepatoblastoma

NCT03400709 2018-01-17

Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

Phase NA Completed

Ototoxicity

NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Phase NA Withdrawn

Ototoxicity, Neoplasms

NCT01451853 2017-09-25

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Phase 2 Unknown

Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT00458887 2017-03-13

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Ototoxicity

NCT00477607 2014-03-07

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

Phase 2/3 Completed

39 enrolled 11 charts

Ototoxicity

NCT00683319 2013-09-20

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

Active not recruiting

Ototoxicity, Central Nervous System Neoplasms

NCT01216800 2010-10-07

Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors

Phase 3 Unknown

Ototoxicity, Head and Neck Neoplasms, Radiation Injuries, Salivary Gland Neoplasms